24-month Prospective, Multicentre, Non-interventional Study to Evaluate the Effectiveness of Elocta Compared to Conventional Factor Products in the Prophylactic Treatment of Patients With Haemophilia A (A-SURE)
Latest Information Update: 04 Oct 2024
At a glance
- Drugs Efmoroctocog alfa (Primary) ; Factor VIII
- Indications Haemophilia A
- Focus Therapeutic Use
- Acronyms A-SURE
- Sponsors Swedish Orphan Biovitrum
- 31 Jan 2024 According to a Sobi media release, pooled analysis of real-world effectiveness and safety of a recombinant Factor VIII Fc in patients with haemophilia A by age groups data to be presented at EAHAD 2024.
- 14 Jun 2023 According to Sanofi Media Release, the company will present new scientific data at ISTH 2023, the 31st Congress of the International Society on Thrombosis and Haemostasis.Nine abstracts have been accepted for presentation.
- 13 Jul 2022 According to a Swedish Orphan Biovitrum media release, results from this trial were presented at the 30th International Society on Thrombosis and Haemostasis (ISTH) Congress, 2022 in London. The results were presented orally by Professor Johannes Oldenburg, the study principal investigator of the study.